Amnio Technology Announces PalinGen® and ProMatrX™ Product Coverage by Palmetto GBA


Phoenix, AZ, USA (June 15, 2016) – Amnio Technology, a manufacturer and distributor of amnion-derived human allografts, announced today that Palmetto GBA will provide Medicare coverage for its PalinGen® and ProMatrX™ line of products.

As the Medicare Administrative Contractor (MAC) for Jurisdiction M Parts A and B, Palmetto GBA is one of the nation’s largest providers of high volume claims and transaction processing, contact center operations and technical services to the federal government and other commercial customers. Jurisdiction M includes the states of North and South Carolina, Virginia and West Virginia. Palmetto GBA joins Novitas Solutions and First Coast Services Options in implementing similar positive coverage determinations related to the use of amnion-derived products manufactured and distributed by Amnio Technology.

The PalinGen® and ProMatrX™ line of products are human allografts processed from healthy placental tissues. Placental tissue and membrane are known to contain collagen substrates, growth factors and extracellular matrix proteins recognized as part of the complex wound healing process. Published studies on the safety and efficacy of amniotic tissue in wounds date back over 100 years. Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, reepithelialization, and anti-fibrotic properties. Therefore, amniotic tissue is considered to be an attractive wound biomaterial.

“The continued expansion of coverage demonstrates an evolving understanding among payers and providers of the clear benefits these unique products offer,” remarked Ethan Minkin, Esq., MSPH, Amnio Technology CEO. “We are committed to supporting further reimbursement access for the Amnio Technology line of products, and advancing their expanded clinical adoption.”

About Amnio Technology, LLC

Amnio Technology is a global leader in the development and use of amnion-­derived technologies. The company is focused on optimizing the regenerative potential and clinical use of these unique tissues. PalinGen® and ProMatrX™ products do not require fetal sacrifice and recovery is performed with maternal consent during elective Cesarean delivery. Donor tissue is recovered using one of the safest recovery techniques and sterile equipment to minimize bioburden contamination. The amniotic tissues are procured through a network of qualified and trained recovery partners, following stringent screening and recovery protocols in a highly controlled processing environment. Amnio Technology enhances the gift of human birth tissue donation by developing, processing and distributing innovative allografts that provide regenerative therapies to improve quality of life.

Amnio Technology, LLC

22510 N 18th Drive

Phoenix, AZ 85027

Phone: 888.232.8550

Fax: 888.232.6750



Michael Derminio, Marketing and Sales Manager

Phone: 888.232.8550 Ext 707

Call Now Button